Melasma is a chronic acquired hyperpigmentation disorder that often exerts a psychosocial burden on affected individuals. Although laser- and light-based therapies are pivotal third-line interventions for recalcitrant cases, clinical consensus regarding their comparative efficacy and long-term safety remains inconsistent. This systematic review and meta-analysis aimed to evaluate and synthesize evidence from randomized controlled trials (RCTs) on the efficacy and safety of various laser-based therapies for melasma. A literature search was performed using PubMed, Excerpta Medica Database (EMBASE), Cochrane Library, and Web of Science databases from inception to January 2026. RCTs and split-face comparative studies evaluating laser therapies versus placebo, topical agents, or alternative laser modalities were included. Data synthesis was performed using a random-effects model with Hartung-Knapp adjustment. The primary outcome was the mean difference (MD) in the reduction of the Melasma Area and Severity Index (MASI) score. The certainty of evidence was appraised using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach. Fifty-two studies, involving 1,058 participants, met the inclusion criteria. The overall pooled analysis showed a trend toward clinical improvement that was not statistically significant (MD: 0.70; 95% CI: -0.55, 1.95; p = 0.2682). Subgroup analysis by laser technology revealed that low-fluence Q-switched Nd:YAG (QSNY) (1064 nm) lasers provided a statistically significant reduction in melasma severity (MD 1.47; 95% CI: 0.08 to 2.85, p < 0.05), while picosecond lasers (MD -0.11; 95% CI: -0.79 to 0.57) and fractional lasers (MD 0.94; 95% CI: -0.84 to 2.71) did not significantly outperform control groups. Statistical heterogeneity was high across the evidence (I² = 96.2%). The overall certainty of evidence for the primary outcome was very low because of the lack of blinding and the high inconsistency. No serious adverse events were reported, although minor complications, such as transient erythema and localized burning, were common. Low-fluence QSNY laser therapy is an effective adjunctive modality for melasma management. However, due to high recurrence rates and variability in outcomes, it should be integrated into a multi-modal approach alongside strict photoprotection and topical depigmenting agents. Future research should prioritize the long-term follow-up and standardization of laser parameters across different skin phenotypes.
Cell Biochemistry and Function · مجلد 44 (10) · e70321-e70321
Patient-derived organoids (PDOs) have emerged as an effective experimental platform for bridging the long-standing gap between traditional in vitro cancer models and the biological complexity of actual tumors. These three-dimensional cultures (3D), derived directly from patient tissues, preserve essential architectural, genomic, and phenotypic characteristics of their tumors of origin, enabling more accurate modeling of tumor heterogeneity and disease evolution. Over the last decade, rapid methodological advances in organoid culture systems, extracellular matrices (ECMs), and growth factor optimization have facilitated the establishment of organoid models for a wide range of malignancies and the development of large living biobanks representing diverse patient populations. These models are increasingly being utilized to study cancer biology, elucidate mechanisms of treatment resistance, and evaluate patient-specific therapeutic responses, highlighting their potential as tools for precision oncology. However, important challenges remain, including incomplete representation of the tumor microenvironment (TME), variability in culture conditions, and limited scalability, and the need for greater standardization and validation. Consequently, although PDOs show considerable promise for translational research and personalized medicine, their routine clinical implementation remains largely investigational, and their clinical utility has not yet been fully established. This review examines the technological foundations of PDO generation, assesses their role as experimental models of tumor biology, and discusses their expanding applications in translational cancer research and precision oncology while highlighting key challenges that must be addressed before their widespread clinical adoption.
Post-acne erythema (PAE) is a persistent acne sequela without an established standard treatment. This systematic review evaluated the comparative efficacy and safety of interventions tested in randomized trials. PubMed/MEDLINE, Scopus, and Web of Science were searched from inception through August 1, 2026. Randomized parallel-group and split-face trials reporting erythema outcomes were eligible. Risk of bias was assessed with the Cochrane Risk of Bias 2 (RoB 2) tool. Heterogeneity precluded meta-analysis, and available findings were synthesized narratively. Nine trials involving 301 participants contributed 11 pairwise comparisons. Against untreated or blank controls, favorable effects were reported for picosecond alexandrite laser, narrow-spectrum vascular intense pulsed light (IPL), and non-cross-linked hyaluronic acid mesotherapy. A 577-nm semiconductor laser showed interim instrumental benefit, but blinded assessors found no final between-side difference. In active-treatment and add-on comparisons, narrow-spectrum IPL was favored over broad-spectrum IPL, neodymium-doped yttrium aluminum garnet (Nd) laser added to low-dose isotretinoin was favored over isotretinoin alone, and 577-nm pro-yellow laser was favored over topical brimonidine. Botulinum toxin type A was favored over broadband light at the earliest assessment only. Fractional laser and pulsed dye laser did not differ significantly, while delicate pulsed light and Q-switched 1064-nm Nd laser showed no sustained difference at the final assessment. Adverse events were mild and transient, although pigmentation and blistering occurred with one broad-spectrum IPL protocol. Five trials had some concerns, and four had high overall risk of bias. Trials suggested potential benefits, but small samples, heterogeneity, short follow-up, and reporting limitations precluded identification of a preferred treatment. Larger, prospectively registered trials using blinded assessment and standardized outcomes are needed.
Frontiers in Pharmacology · مجلد 17 · 1822157-1822157
Background: The worldwide burden of metabolic dysfunction-associated steatotic liver disease (MASLD) is rising sharply, powered by high prevalence of obesity and its associated metabolic insults. Though urgent, definitive treatment is not yet available. Empagliflozin, a sodium glucose co-transporter inhibitor has been suggested in both human and animal studies to have diverse beneficial effects in MASLD by anti-inflammation and anti-oxidative stress effects, but many of the underlying mechanisms remain unexplained. The main aim of this systematic review and meta-analysis was to evaluate the effects of empagliflozin's in preclinical animal studies trying to view new horizons for future treatment of MASLD. Methods: we searched the related animal preclinical studies in databases including Scopus, Web of Science, Cochrane library, Wily online library and PubMed. The research team screened the literature and extracted data; any discrepancies were resolved by the research team leader through discussion. The quality of research methods was assessed by SYRCLE (systematic review center for laboratory animal experimentation) risk of bias tool. The meta-analysis was guided by the Cochrane Handbook; statistical analyses were conducted via RevMan 5.4 offline version and Comprehensive Met analysis V3 software. Results: Our meta-analysis included 17 studies, involving 584 animals. In comparison with the model group, empagliflozin significantly reduced steatosis markers including hepatic burden of lipids, including triglycerides and cholesterol, NAFLD Activity Score (NAS) and total serum cholesterol (TC). It also significantly reduced hepatic fibrosis markers including fibrosis grade, transforming growth factor-β (TGF-β) and collagen type I alpha 1 chain) COL1A1). Beyond its anti-steatofibrotic effects, empagliflozin significantly downregulated hepatic expression of inflammatory and oxidative markers including tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6) and malondialdehyde (MDA). Moreover, empagliflozin significantly improved glycemic indices including Homeostatic Model Assessment for Insulin Resistance (HOMA-IR), serum insulin, and fasting blood sugar (FBS). Conclusion: Empagliflozin significantly protected the liver against steatosis and fibrosis by mitigating hepatic inflammation, oxidative stress and insulin resistance.
Child sexual abuse (CSA) evaluations frequently yield normal or nonspecific anogenital findings, even in cases later substantiated through investigation. This reality is often misunderstood in clinical, legal, and multidisciplinary contexts, where the absence of physical injury may be incorrectly interpreted as the absence of abuse. The purpose of this narrative review is to explain why most CSA examinations are normal and to provide an evidence-based framework for interpreting and communicating these findings in a manner that is medically accurate and forensically defensible. A targeted review of contemporary guidelines, large clinical series, healing studies, forensic evidence collection literature, and sexually transmitted infection (STI) testing recommendations was conducted. Evidence consistently demonstrates that low physical yield is driven by several converging factors: the nature of abusive acts, the elasticity and rapid healing capacity of pediatric anogenital tissues, delayed disclosure leading to non-acute examinations, variability in examiner experience and documentation quality, and the time-sensitive nature of biological evidence recovery. STI findings are uncommon overall and require contextual interpretation, including consideration of testing methods and potential nonsexual transmission pathways. Importantly, a normal examination neither confirms nor excludes CSA. Misinterpretation commonly arises from imprecise terminology, binary reasoning, and overreliance on physical findings as proof. This review emphasizes the need for standardized, evidence-based communication in medical reports and testimony to prevent medico-legal misunderstanding. Practical language guidance is provided to assist clinicians in accurately conveying the limitations and significance of normal findings. Understanding that "normal is common" in CSA evaluations is essential to reducing harm, supporting trauma-informed care, and strengthening the integrity of multidisciplinary decision-making.
child sexual abuseanogenital examinationnormal findingssexually transmitted infections
Introduction: Metabolic bone disease of prematurity (MBDP) affects up to 30 % of very low birth weight infants; however, evidence regarding prevention and treatment strategies remains limited. We aimed to evaluate the efficacy and safety of nutritional, mechanical, and pharmacological interventions for MBDP. Methods: Following PRISMA 2020 guidelines, we searched five databases from inception to May 5, 2025, for studies evaluating interventions for MBDP in preterm infants (<37 weeks or <1500g). Primary outcomes included MBDP incidence, bone mineral density, and safety profiles. Random-effects meta-analyses, trial sequential analysis (TSA), and GRADE assessments were conducted. Results: Eighteen studies (1577 infants) from ten countries met inclusion criteria. Nutritional prophylaxis significantly reduced MBDP incidence by 54 % (risk ratio [RR] = 0.46, 95 % confidence interval [CI] 0.30-0.68, P-value<0.001), with early calcium/phosphorus supplementation achieving 74-84 % risk reduction. TSA confirmed conclusive evidence, with cumulative Z-score (-5.99) crossing the O'Brien-Fleming boundary at 270.9 % of required information size. Number needed to treat was five at 40 % baseline risk. Mechanical interventions improved bone mineral content by 28 % (P-value<0.01), quantitative ultrasound speed-of-sound (mean difference [MD] = 75.3 m/s, 95 % CI 45.2-105.4), and weight gain (MD = 5.11 g/kg/day, 95 % CI 3.95-6.27). Both interventions demonstrated favorable safety profiles, with mechanical protocols reporting no adverse events. Conclusions: Nutritional prophylaxis conclusively reduces MBDP incidence, while mechanical interventions effectively improve bone mineralization. Although no studies directly evaluated combined approaches, the complementary mechanisms of nutritional and mechanical interventions suggest that optimal prevention may involve integrating both strategies. Critical gaps persist in orthopedic management, necessitating future research on fracture protocols and surgical interventions.
metabolic bone disease of prematuritypreterm infantsvery low birth weight infantscalcium and phosphorus supplementation
Introduction: Pediatric idiopathic intracranial hypertension (IIH) and growth plate disorders (GPD) show parallel epidemiological trends and carry possible pathophysiological links, especially regarding obesity and hormonal dysregulation. This study investigated their indirect relationship through structural equation modeling (SEM) to identify age-dependent mechanisms and guide precision treatment strategies. Methods: Following PRISMA 2020 guidelines, we searched literature databases from inception to May 15, 2025, identifying studies reporting pediatric IIH and/or GPD parameters. SEM analysis was performed with age-stratified models to evaluate the mediating effects of obesity and hormonal factors between prepubertal (<10-12 years) and postpubertal (>10-12 years) cohorts. Results: We included 22 eligible studies with total of 2293 individuals. SEM revealed peculiar age-dependent mechanisms. In prepubertal children, venous pressure (β = 0.68, P-value<0.001) and vitamin D/hormonal pathways (β = 0.56, P-value<0.001) dominated, with obesity showing minimal effect (β = 0.28, P-value = 0.001). In a controverse manner, in postpubertal patients, the obesity pathway predominated (β = 0.76, P-value<0.001) with reduced venous (β = 0.29, P-value = 0.003) and hormonal (β = 0.16, P-value = 0.038) contributions. Mechanism-specific therapeutic efficacy showed parallel patterns: acetazolamide/surgical interventions were superior for venous-dominant cases (g = 1.86/1.74), while weight management demonstrated greatest efficacy for obesity-dominant phenotypes (g = 1.75). Vitamin D supplementation showed significant benefit only in hormonal-dominant cases (g = 1.64). Conclusions: Pediatric IIH demonstrates fundamental mechanistic heterogeneity across development. A puberty-associated shift from venous/hormonal to obesity-dominant mechanisms explains the changing demographics and provides a framework for precision treatment. Targeted therapeutic approaches based on dominant mechanisms showed 63% improved outcomes compared to standard of care of IIH.
BACKGROUND: Whole-slide imaging (WSI) has shifted pathology toward digital workflows, creating the foundation for applying artificial intelligence (AI) to diagnostic tasks. This review summarises validated AI applications in diagnostic pathology, with an emphasis on clinical performance, regulatory developments and the practical barriers that affect implementation. METHODS: A structured search of PubMed, Scopus and Google Scholar identified English-language, peer-reviewed studies from January 2020 to May 2025. Eligible studies applied AI to diagnostic, grading or prognostic tasks in human tissue, used a pathologist-confirmed reference standard and included external or multi-centre validation. RESULTS: More than 150,000 digital slides were represented across the included studies. Reported performance metrics demonstrated strong diagnostic accuracy across several validated applications. Large meta-analyses and externally validated studies reported sensitivity values exceeding 96% and specificity above 93% for selected cancer-detection tasks, while other studies demonstrated high agreement for Gleason grading (QWK up to 0.862) and biomarker quantification (Ki-67 ICC 0.98). CONCLUSION: AI has the capacity to strengthen diagnostic pathology by improving consistency, measurement and efficiency. Moving from experimental use to routine reporting will require broad validation across centres, enhanced model transparency, strong quality-assurance systems and close cooperation between developers and pathologists.
Background: Chemical peels are widely used for mild-to-moderate acne vulgaris, but comparative evidence is dispersed across small trials and multiple active formulations. This review synthesized the supplied randomized evidence and compared efficacy and tolerability across peel types using network meta-analysis. Methods: PubMed, the Cochrane Library, Scopus, and Web of Science were searched for randomized active-comparator trials of chemical peels for acne vulgaris up to June 2026. Random-effects network meta-analyses used standardized mean differences (SMDs) for continuous outcomes and risk ratios (RRs) for categorical and safety outcomes, each with 95% confidence intervals (CIs). Salicylic acid was the reference treatment, and treatments were ranked using surface under the cumulative ranking curve (SUCRA) values. Results: Twenty-three randomized trials with reported enrollment totaling 1,170 participants were included. Most continuous efficacy comparisons were not statistically significant. Relative to salicylic acid, Jessner's solution was associated with a smaller reduction in papule count (SMD 2.49, 95% CI 1.28 to 3.70) and a smaller reduction in Michaelsson acne score (SMD 1.78, 95% CI 0.41 to 3.16). Salicylic plus mandelic acid ranked highest for good improvement (SUCRA 91.9%), but its RR versus salicylic acid was imprecise (RR 1.96, 95% CI 0.75 to 5.13). Trichloroacetic acid was associated with more erythema than salicylic acid (RR 2.74, 95% CI 1.10 to 6.78). Heterogeneity was substantial for non-inflammatory lesion count, papule count, pustule count, and Michaelsson acne score. Treatment-label fragmentation and undocumented handling of split-face correlations limited confidence in rankings. Conclusion: Our analysis does not establish broad superiority of one chemical peel for acne vulgaris. Salicylic acid performed favorably against Jessner's solution for selected efficacy outcomes and had a lower erythema risk than trichloroacetic acid, but most estimates were imprecise and several networks were heterogeneous. Treatment choice should remain individualized, and the findings require confirmation in rigorously reported head-to-head trials with standardized outcomes.
chemical peelsacnesalicylic acidJessner's solution
The continuous progression of cancerous severity due to the interaction of physical (ultraviolet radiation), chemical (smoking, mycotoxins, and heavy metals), and biological (microbial populations) carcinogens inspired scientists to develop a correlation between active therapeutic agents and cancer proliferation. This review highlights the molecular mechanism by which lycopene imparts its anticancerous role, focusing on clinical and animal trials to validate its effectiveness. The antioxidant profile of lycopene promotes anticancerous properties that reduce cancer prevalence by activating cell signaling pathways and gene expression (involved in cancer cell proliferation). Lycopene's anti-inflammatory properties suppresses the tumor growth and development-promoting pathways, such as the PI3K/Akt/mTOR pathway. The anticancer property of lycopene is also evidenced by its inhibitory potential of the Wnt/β-catenin signaling pathway that is involved in cancer cell modulation and propagation. Lycopene also suppresses and neutralizes oxidative stress and reactive oxygen species (ROS)-induced DNA damage, preventing gene mutation. Inflammation-induced cell death is mitigated by lycopene's anti-inflammatory potential that lowers the expression of interleukin 6 (IL-6) and tumor necrosis factor-alpha (TNF-α). Several clinical and randomized control trials have revealed the effect of lycopene supplementation in the management of cancer, including breast cancer, pancreatic cancer, prostate cancer, colon cancer, ovarian cancer, skin cancer, oral cancer, liver cancer, gastric cancer, and kidney cancer, by lessening prostate-specific antigen (PSA) levels. These studies also accentuate certain limitations that need further trials to evaluate the long-term consequences of lycopene supplementations and their specific effective dose.
The rising demand for skin-lightening products has brought glutathione, a tripeptide with antioxidant properties and melanogenesis-regulating effects, into focus as a potentially safer alternative to conventional agents. This narrative review aims to evaluate the efficacy and safety of oral, topical, and intravenous glutathione in skin-lightening therapies. Oral administration shows significant but variable decreases in melanin levels with limited side effects. Topical formulations provide good-level melanin reduction and skin texture improvement but with varying sustainability. Intravenous glutathione, although having rapid action, is associated with serious safety concerns like anaphylaxis and hepatotoxicity, further aggravated by a lack of standardized dosing protocols. Current evidence supports glutathione's potential as a depigmenting agent but underscores the need for rigorous, large-scale clinical trials to establish long-term safety, optimal dosing, and standardized applications. Until such data are available, clinicians and consumers should exercise caution to ensure safe and effective dermatological practices, particularly with intravenous use.
AIM: To evaluate the efficacy and outcomes of integrative technologies employed in nursing-led interventions for the management of diabetes. BACKGROUND: With the global rise in diabetes prevalence, there is growing interest in digital health solutions to improve disease self-management. Nurses are increasingly leveraging technologies, such as mobile applications, wearable devices, and telehealth platforms, to support individuals with diabetes. However, the effectiveness and implementation outcomes of such nursing-led digital interventions remain variably reported in the literature. METHODS: A systematic review was conducted following PRISMA 2020 guidelines. Comprehensive five database searches (PubMed, CINAHL, Scopus, Web of Science, and Embase) identified randomized controlled trials (RCTs) from 2013 to 2024. Studies were included if they involved nurse-led interventions incorporating digital technologies for diabetes management. Data were synthesized using narrative and thematic analysis. Risk of bias was assessed using the RoB 2 tool. RESULTS: Thirteen RCTs involving diverse technologies demonstrated improvements in glycemic control (HbA1c reduction), self-management behaviors, and quality of life. Interventions incorporating personalized coaching, regular follow-up, and patient-centered feedback were particularly effective. Most studies were rated as low risk of bias, though some showed concerns regarding reporting practices and intervention fidelity. CONCLUSION: Nursing-led digital health interventions can significantly enhance diabetes care outcomes. Their success is contingent upon sustained patient engagement, nurse training, and organizational support. Broader implementation requires addressing digital literacy and system-level integration challenges. IMPLICATIONS FOR PRACTICE: Nurse-led technologies should be embedded in care models to support scalable, personalized, and effective diabetes self-management across diverse settings. CLINICAL TRIAL NUMBER: Not applicable.
diabetes managementnurse-led interventiondigital health technologiesmobile health apps
Telehealth adoption gained popularity during the coronavirus disease 2019 (COVID-19) pandemic and had substantial and various impacts on patient outcomes depending on the specific environment, healthcare system, and quality of telehealth services supplied. Hence, this systematic review explored those impacts and their sustainability post-pandemic. To conduct this systematic review, a thorough literature search was undertaken in electronic databases such as PubMed, Medline, Web of Science, Google Scholar, databases, Embase, and PsycINFO using relevant keywords. We included articles written in English and published in the last 10 years that reported on the impact of telehealth adoption on various patient outcomes and the impact of sustainability post-pandemic. The findings of this systematic review highlight the remarkable impact of telehealth adoption on patient outcomes and the sustainability of these initiatives post-pandemic. Telehealth has proven to enhance various aspects of healthcare, spanning from prevention to follow-up. Another effect of telehealth adoption is the significant reduction in hospitalizations. Furthermore, telehealth profoundly impacts hospital stays, leading to a decrease in all-cause hospital days per patient by 1.07 (95% confidence interval (CI): 1.76 to 0.39) days and a shorter mean hospital stay for condition-related hospitalizations by 89% (95% CI 1.42 to 0.36), providing evidence of efficient healthcare delivery. There was also a reduction in mortality rates for patients receiving telemedicine interventions. Telehealth is also cost-effective while remaining highly effective. Patient satisfaction is another key outcome of telehealth adoption observed. The convenience and reduced expenses of telehealth have garnered positive feedback from patients, reinforcing the desirability of telehealth as a viable alternative to in-person visits. Despite these numerous benefits, barriers and disparities in telehealth adoption and utilization persist, especially in rural hospitals that face challenges, including a lack of Health Information Exchange (HIE) capacity, limited patient engagement capabilities, and the absence of financial reimbursement. This systematic review underscores the remarkable impact of telehealth adoption on patient outcomes and its sustainability post-pandemic. However, barriers and disparities still exist, requiring attention to ensure equitable access to telehealth services. The evidence supports the continued development and implementation of telehealth initiatives to improve healthcare delivery and patient outcomes post-pandemic.
BACKGROUND: Primary osteoblasts are essential for bone formation and regeneration, making them pivotal in dental applications, including periodontal regeneration, ridge augmentation, and implant osseointegration. Sourced from various tissues like alveolar bone, calvarial bone, mandibular and maxillary bones, long bones, and bone marrow-derived stem cells (BMSCs), each type of osteoblast presents unique advantages and limitations related to yield, accessibility, and clinical relevance. Given these variables, selecting an appropriate source is crucial for experimental consistency and translational application in dentistry. METHODS: This review synthesizes data from in vitro, animal, and clinical studies to provide a comprehensive overview of osteoblast sourcing, isolation, and characterization in dental research. Sources were reviewed based on yield, anatomical relevance, and accessibility, while isolation methods were compared to assess their impact on cell behavior and phenotype retention. The review evaluates methods such as enzymatic digestion, explant culture, and differentiation of BMSCs, alongside characterization techniques like morphological analysis, gene expression profiling, and mineralization assays. RESULTS: The analysis shows that alveolar bone-derived osteoblasts offer high clinical relevance due to their anatomical similarity to oral structures but are limited by low yield and invasive collection. Calvarial and long bone osteoblasts provide higher yields, making them useful for material testing, though they lack biomechanical compatibility with oral environments. BMSCs offer a renewable source with significant regenerative potential but require precise differentiation protocols. In vitro studies contribute mechanistic insights, while animal models bridge the gap to clinical application, despite challenges in standardization and interspecies variability. CONCLUSION: This review highlights the importance of selecting appropriate osteoblast sources and methods for dental research to optimize outcomes in periodontal and implant-related therapies. The variability across study designs and experimental outcomes underscores the need for standardized protocols and targeted systematic reviews within specific research settings. These findings offer a framework for future osteoblast-based research and guide the effective translation of osteoblast therapies into clinical dental practice.
osteoblast isolationdental tissue regenerationbone marrow-derived stem cellsalveolar bone